Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review

Hitesh Jagani, Narayanan Kasinathan, Sreenivasa Reddy Meka, Josyula Venkata Rao

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

Original languageEnglish
Pages (from-to)1212-1221
Number of pages10
JournalArtificial Cells, Nanomedicine and Biotechnology
Volume44
Issue number5
DOIs
Publication statusPublished - 03-07-2016

Fingerprint

RNA Interference
RNA
Proteins
bcl-2 Genes
Antisense RNA
Oncology
Small Interfering RNA
Neoplasms
Genes
Cells
Technology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

Jagani, Hitesh ; Kasinathan, Narayanan ; Meka, Sreenivasa Reddy ; Venkata Rao, Josyula. / Antiapoptotic Bcl-2 protein as a potential target for cancer therapy : A mini review. In: Artificial Cells, Nanomedicine and Biotechnology. 2016 ; Vol. 44, No. 5. pp. 1212-1221.
@article{eefa812640924c2cbad2369f09aff595,
title = "Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review",
abstract = "Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.",
author = "Hitesh Jagani and Narayanan Kasinathan and Meka, {Sreenivasa Reddy} and {Venkata Rao}, Josyula",
year = "2016",
month = "7",
day = "3",
doi = "10.3109/21691401.2015.1019668",
language = "English",
volume = "44",
pages = "1212--1221",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "5",

}

Antiapoptotic Bcl-2 protein as a potential target for cancer therapy : A mini review. / Jagani, Hitesh; Kasinathan, Narayanan; Meka, Sreenivasa Reddy; Venkata Rao, Josyula.

In: Artificial Cells, Nanomedicine and Biotechnology, Vol. 44, No. 5, 03.07.2016, p. 1212-1221.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antiapoptotic Bcl-2 protein as a potential target for cancer therapy

T2 - A mini review

AU - Jagani, Hitesh

AU - Kasinathan, Narayanan

AU - Meka, Sreenivasa Reddy

AU - Venkata Rao, Josyula

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

AB - Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

UR - http://www.scopus.com/inward/record.url?scp=84976597114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976597114&partnerID=8YFLogxK

U2 - 10.3109/21691401.2015.1019668

DO - 10.3109/21691401.2015.1019668

M3 - Review article

C2 - 25801037

AN - SCOPUS:84976597114

VL - 44

SP - 1212

EP - 1221

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 5

ER -